01433nam 2200385Ia 450 991069906050332120090818141011.0(CKB)5470000002399280(OCoLC)430960220(EXLCZ)99547000000239928020090818d2005 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] development and use of risk minimization action plansRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,[2005]1 online resource (23 pages)"Center for Biologics Evaluation and Research (CBER)"."Clinical medical"."March 2005".Guidance for industry DrugsSide effectsPreventionGovernment policyUnited StatesBiologicalsGovernment policyUnited StatesDrugsSide effectsPreventionGovernment policyBiologicalsGovernment policyCenter for Drug Evaluation and Research (U.S.)Center for Biologics Evaluation and Research (U.S.)GPOGPOBOOK9910699060503321Guidance for industry3434577UNINA